Our Science

OUR PIPELINE

Through pioneering science and an unwavering commitment to patients, Alnylam has led the translation of the breakthrough discovery of RNA interference (RNAi) into an entirely new class of medicines that is disrupting disease.

Our robust pipeline of investigational RNAi therapeutics is currently focused on diseases with high unmet need in several therapeutic areas. Additionally, we will follow the science and are continually looking at how we can use our technology to help new patient populations.

Learn more about RNAi and our science ›

Learn more about current Alnylam clinical trials ›